Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2012 Oct 17;10(10):CD003265.
doi: 10.1002/14651858.CD003265.pub3.

Methenamine hippurate for preventing urinary tract infections

Bon San B Lee  1 , Tushar Bhuta, Judy M Simpson, Jonathan C Craig
Affiliations
Meta-Analysis

Methenamine hippurate for preventing urinary tract infections

Bon San B Lee et al. Cochrane Database Syst Rev. .

Abstract

Background: Methenamine salts are often used as an alternative to antibiotics for the prevention of urinary tract infection (UTI). This review was first published in Issue 1, 2002 and updated in Issue 4, 2007.

Objectives: To assess the benefits and harms of methenamine hippurate in preventing UTI.

Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL in The Cochrane Library), MEDLINE (from 1950), EMBASE (from 1980), reference lists of articles and abstracts from conference proceedings without language restriction. Manufacturers' of methenamine salts were contacted for unpublished studies and contact was made with known investigators.Date of last search: June 2012

Selection criteria: Randomised controlled trials (RCT) and quasi-RCTs of methenamine hippurate used for the prevention of UTIs in all population groups were eligible. A comparison with a control/no treatment group was a prerequisite for selection.

Data collection and analysis: Two authors independently assessed study quality and extracted data. Statistical analyses were performed using the random effects model and the results expressed as risk ratio (RR) for dichotomous outcomes with 95% confidence intervals (CI). An exploration of heterogeneity and a detailed description of results, grouped by population, was undertaken.

Main results: Thirteen studies (2032 participants) were included. Six studies (654 patients) reported symptomatic UTI and eight studies (796 patients) reported bacteriuria. Overall, study quality was mixed. The overall pooled estimates for the major outcome measures were not interpretable because of underlying heterogeneity. Subgroup analyses suggested that methenamine hippurate may have some benefit in patients without renal tract abnormalities (symptomatic UTI: RR 0.24, 95% CI 0.07 to 0.89; bacteriuria: RR 0.56, 95% CI 0.37 to 0.83), but not in patients with known renal tract abnormalities (symptomatic UTI: RR 1.54, 95% CI 0.38 to 6.20; bacteriuria: RR 1.29, 95% CI 0.54 to 3.07). For short-term treatment duration (1 week or less) there was a significant reduction in symptomatic UTI in those without renal tract abnormalities (RR 0.14, 95% CI 0.05 to 0.38). The rate of adverse events was low.

Authors' conclusions: Methenamine hippurate may be effective for preventing UTI in patients without renal tract abnormalities, particularly when used for short-term prophylaxis. It does not appear to work in patients with neuropathic bladder or in patients who have renal tract abnormalities. The rate of adverse events was low, but poorly described.There is a need for further large well-conducted RCTs to clarify this question, particularly for longer term use for people without neuropathic bladder.

PubMed Disclaimer

Conflict of interest statement

  1. Dr Lee is the lead investigator on the NHMRC Project Grant Application: 630448 Probiotic Prophylaxis of Spinal Cord Injury Urinary Tract‐Infection TherapeUtic‐Trial (ProSCIUTTU), which is an Australian government sponsored study looking at the effectiveness of Probiotic therapy in preventing Urinary tract infection and multi drug resistance (Lee 2007). This study was independently assessed by the Cochrane Renal Group's Review Group Coordinator to eliminate potential bias in the assessment of this study.

  2. Tushar Bhuta: none known

  3. Judy M Simpson: none known

  4. Jonathan C Craig: none known

Figures

1.1
1.1. Analysis
Comparison 1 Symptomatic UTI (confirmed by positive urine test), Outcome 1 Symptomatic bacteruria.
1.2
1.2. Analysis
Comparison 1 Symptomatic UTI (confirmed by positive urine test), Outcome 2 Symptomatic bacteruria: Renal tract abnormalities.
1.3
1.3. Analysis
Comparison 1 Symptomatic UTI (confirmed by positive urine test), Outcome 3 Sensitivity analysis: Symptomatic UTI including subjects unconfirmed by positive urine tests (for Lee 2006)..
1.4
1.4. Analysis
Comparison 1 Symptomatic UTI (confirmed by positive urine test), Outcome 4 Duration of therapy.
1.5
1.5. Analysis
Comparison 1 Symptomatic UTI (confirmed by positive urine test), Outcome 5 Short duration treatment (7 days or less): Upper renal tract abnormalities.
2.1
2.1. Analysis
Comparison 2 Bacteriuria, Outcome 1 Outcome measure: Bacteriuria.
2.2
2.2. Analysis
Comparison 2 Bacteriuria, Outcome 2 Bacteriuria (renal tract abnormalities).
2.3
2.3. Analysis
Comparison 2 Bacteriuria, Outcome 3 Duration of therapy.
2.4
2.4. Analysis
Comparison 2 Bacteriuria, Outcome 4 Short duration treatment (7 days or less): (upper renal tract abnormalities).
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Furness 1975 {published data only}
    1. Furness ET, McDonald PJ, Beasley NV. Urinary antiseptics in asymptomatic bacteriuria of pregnancy. New Zealand Medical Journal 1975;81(539):417‐9. [MEDLINE: ] - PubMed
Gundersen 1986 {published data only}
    1. Gundersen R, Hoivik HO, Osmundsen K. Frequent cystitis in elderly women. A double‐blind comparison of hiprex and placebo in general practice [Hyppig forekommende cystitter hos eldre kvinner]. Tidsskrift for Den Norske Laegeforening 1986;106(25):2048‐9. [MEDLINE: ] - PubMed
Hoivik 1984 {published data only}
    1. Hoivik H. O, Gundersen R, Osmundsen K, Halvorsen P, Hjortdahl P, Stokke JG. Prevention of recurrent cystitis in fertile women. A double‐blind comparison of hiprex and placebo in general practice. Tidsskrift for Den Norske Laegeforening 1984;104(16):1150‐2. [MEDLINE: ] - PubMed
Kasanen 1982 {published data only}
    1. Kasanen A, Junnila SY, Kaarsalo E, Hajba A, Sundquist H. Secondary prevention of recurrent urinary tract infections. Comparison of the effect of placebo, methenamine hippurate, nitrofurantoin and trimethoprim alone. Scandinavian Journal of Infectious Diseases 1982;14(4):293‐6. [MEDLINE: ] - PubMed
Knoff 1985 {published data only}
    1. Knoff T. Methenamine hippurate. Short‐term catheterization in gynecologic surgery. A double‐blind comparison of hiprex and placebo. Tidsskrift for Den Norske Laegeforening 1985;105(7):498‐9. [MEDLINE: ] - PubMed
Kuhlemeier 1985 {published data only}
    1. Kuhlemeier KV, Stover SL, Lloyd LK. Prophylactic antibacterial therapy for preventing urinary tract infections in spinal cord injury patients. Journal of Urology 1985;134(3):514‐7. [MEDLINE: ] - PubMed
Ladehoff 1984 {published data only}
    1. Ladehoff P, Jacobsen JC, Olsen H, Pedersen GT, Sorensen T. The preventive effect of methenamine hippurate (haiprex) on urinary infections after short‐term catheterization. A clinical study [Metenaminhippurats (Haiprex) profylaktiske virkning over for urinvejsinfektion ved korttidskateterisation]. Ugeskrift for Laeger 1984;146(19):1433‐4. [MEDLINE: ] - PubMed
Lee 2007 {published and unpublished data}
    1. Lee BB, Haran MJ, Hunt LM, Simpson JM, Marial O, Rutkowski SB, et al. Spinal‐injured neuropathic bladder antisepsis (SINBA) trial. Spinal Cord 2007;45(8):542‐50. [MEDLINE: ] - PubMed
Pettersson 1989 {published data only}
    1. Pettersson B, Tiselius HG. Are prophylactic antibiotics necessary during extracorporeal shockwave lithotripsy?. British Journal of Urology 1989;63(5):449‐52. [MEDLINE: ] - PubMed
Sander 1976 {published data only}
    1. Sander S, Jakobsen A Jr. Preventive hiprex in urinary tract operations. Tidsskrift for Den Norske Laegeforening 1976;96(3):167‐9. [MEDLINE: ] - PubMed
Schiotz 2002 {published data only}
    1. Schiotz HA. Personal communication 15 October 2006.
    1. Schiotz HA, Guttu K. Value of urinary prophylaxis with methenamine in gynecologic surgery. Acta Obstetricia et Gynecologica Scandinavica 2002;81(8):743‐6. [MEDLINE: ] - PubMed
Thomlinson 1968 {published data only}
    1. Thomlinson J, Williams JD, Cope E. Persistence of bacteriuria following gynaecological surgery: A trial of methenamine hippurate. British Journal of Urology 1968;40(4):479‐82. [MEDLINE: ] - PubMed
Tyreman 1986 {published data only}
    1. Tyreman NO, Andersson PO, Kroon L, Orstam S. Urinary tract infection after vaginal surgery. Effect of prophylactic treatment with methenamine hippurate. Acta Obstetricia et Gynecologica Scandinavica 1986;65(7):731‐3. [MEDLINE: ] - PubMed

References to studies excluded from this review

Banovac 1991 {published data only}
    1. Banovac K, Wade N, Gonzalez F, Walsh B, Rhamy RK. Decreased incidence of urinary tract infections in patients with spinal cord injury: effect of methenamine. Journal of the American Paraplegia Society 1991;14(2):52‐4. [MEDLINE: ] - PubMed
Brumfitt 1981 {published data only}
    1. Brumfitt W, Cooper J, Hamilton‐Miller JM. Prevention of recurrent urinary infections in women: a comparative trial between nitrofurantoin and methenamine hippurate. Journal of Urology 1981;126(1):71‐4. [MEDLINE: ] - PubMed
Brumfitt 1983 {published data only}
    1. Brumfitt W, Hamilton‐Miller JM, Gargan RA, Cooper J, Smith GW. Long‐term prophylaxis of urinary infections in women: comparative trial of trimethoprim, methenamine hippurate and topical povidone‐iodine. Journal of Urology 1983;130(6):1110‐4. [MEDLINE: ] - PubMed
Casselman 1966 {published data only}
    1. Casselman J. Hexamethylene‐tetramine hippurate in the treatment of urinary infections. Acta Urologica Belgica 1966;34(3):354‐8. [MEDLINE: ] - PubMed
Chrapowicki 1975 {published data only}
    1. Chrapowicki T, Krzyzanowska‐Rogozinska T, Kurowska D. Treatment of acute and chronic urinary tract infections in children with an urinary chemotherapeutic agent. Zeitschrift fur Allgemeinmedizin 1975;51(27):1215‐9. [MEDLINE: ] - PubMed
Christopher 1969 {published data only}
    1. Christopher LJ, Thompson GR. A trial of hippramine in the treatment of bacteriuria of pregnancy. Irish Journal of Medical Science 1969;8(7):331‐7. [MEDLINE: ] - PubMed
Cronberg 1987 {published data only}
    1. Cronberg S, Welin CO, Henriksson L, Hellsten S, Persson KM, Stenberg P. Prevention of recurrent acute cystitis by methenamine hippurate: double blind controlled crossover long term study. British Medical Journal Clinical Research Ed 1987;294(6586):1507‐8. [MEDLINE: ] - PMC - PubMed
Elo 1978 {published data only}
    1. Elo J, Sarna S, Ahava K, Lepo A. Methenamine hippurate in urinary tract infections in children: prophylaxis, treatment and side effects. Journal of Antimicrobial Chemotherapy 1978;4(4):355‐65. [MEDLINE: ] - PubMed
Genster 1970 {published data only}
    1. Genster HG, Madsen PO. Urinary tract infections following transurethral prostatectomy: with special reference to the use of antimicrobials. Journal of Urology 1970;104(1):163‐8. [MEDLINE: ] - PubMed
Gerstein 1968 {published data only}
    1. Gerstein AR, Okun R, Gonick HC, Wilner HI, Kleeman CR, Maxwell MH. The prolonged use of methenamine hippurate in the treatment of chronic urinary tract infection. Journal of Urology 1968;100(6):767‐71. [MEDLINE: ] - PubMed
Gow 1974 {published data only}
    1. Gow JG. A comparative trial of hexamine hippurate and hexamine mandelate in prevention of recurrent infection of the urinary tract. Practitioner 1974;213(1273):97‐101. [MEDLINE: ] - PubMed
Horcickova 1986 {published data only}
    1. Horcickova M, Prat V, Hatala M, Nezadalova E, Milotova Z. Methenamine hippurate VUFB and mandelamine VUFB in the prevention of recurrent dysuria in women. Casopis Lekaru Ceskych 1986;125(27):849‐53. [MEDLINE: ] - PubMed
Kasanen 1974a {published data only}
    1. Kasanen A, Kaarsalo E, Hiltunen R, Soini V. Comparison of long‐term, low‐dosage nitrofurantoin, methenamine hippurate, trimethoprim and trimethoprim‐sulphamethoxazole on the control of recurrent urinary tract infection. Annals of Clinical Research 1974;6(5):285‐9. [MEDLINE: ] - PubMed
Kasanen 1974b {published data only}
    1. Kasanen A, Mustakallio E, Koskinen EH, Soini V. Methenamine hippurate in the treatment of urinary tract infections. Annals of Clinical Research 1974;6(5):279‐84. [MEDLINE: ] - PubMed
Klein 1976 {published data only}
    1. Klein D, Puchegger R. Methenamine hippurate in urinary tract infections. Zfa ‐ Zeitschrift Fur Allgemeinmedizin 1976;52(21):1110‐4. [MEDLINE: ] - PubMed
Kostiala 1982 {published data only}
    1. Kostiala AA, Nyren P, Runeberg L. Effect of nitrofurantoin and methenamine hippurate prophylaxis on bacteria and yeasts in the urine of patients with an indwelling catheter. Journal of Hospital Infection 1982;3(4):357‐64. [MEDLINE: ] - PubMed
Krechnakova 1979 {published data only}
    1. Krechnakova A, Dzurik R. Prevention of chronic pyelonephritis relapses using metenamine hipuran (author's transl). Casopis Lekaru Ceskych 1979;118(13):402‐4. [MEDLINE: ] - PubMed
LeBlanc 1964 {published data only}
    1. LeBlanc AQL, McGanity WJ. The impact of bacteriuria in pregnancy ‐ a survey of 1300 pregnant patients. Texas Reports on Biology & Medicine 1964;22:336‐47. [MEDLINE: ] - PubMed
Murray 1977 {published data only}
    1. Murray CP, Feeney J. A comparison of hexamine hippurate and sulphamethizolein patients with indwelling catheters following pelvic‐floor surgery. Irish Medical Journal 1977;69(4):97‐8. [MEDLINE: ] - PubMed
Nilsson 1975 {published data only}
    1. Nilsson S. Long‐term treatment with methenamine hippurate in recurrent urinary tract infection. Acta Medica Scandinavica 1975;198(1‐2):81‐5. [MEDLINE: ] - PubMed
Norberg‐A 1980 {published data only}
    1. Norberg A, Norberg B, Parkhede U, Gippert H, Lundbeck K. Randomized double‐blind study of prophylactic methenamine hippurate treatment of patients with indwelling catheters. European Journal of Clinical Pharmacology 1980;18(6):497‐500. [MEDLINE: ] - PubMed
Norberg‐B 1979a {published data only}
    1. Norberg B, Norberg A, Parkhede U, Gippert H. Effect of short‐term high‐dose treatment with methenamine hippurate on urinary infection in geriatric patients with an indwelling catheter. IV. Clinical evaluation. European Journal of Clinical Pharmacology 1979;15(5):357‐61. [MEDLINE: ] - PubMed
Norberg‐B 1979b {published data only}
    1. Norberg B, Norberg A, Parkhede U, Gippert H, Akerman M. The effect of short‐term high‐dose treatment with methenamine hippurate of urinary infection in geriatric patients with indwelling catheters. I. The preparation and morphology of a quantified urine sediment. Upsala Journal of Medical Sciences 1979;84(1):67‐74. [MEDLINE: ] - PubMed
Nyren 1981 {published data only}
    1. Nyren P, Runeberg L, Kostiala AI, Renkonen OV, Roine R. Prophylactic methenamine hippurate or nitrofurantoin in patients with an indwelling urinary catheter. Annals of Clinical Research 1981;13(1):16‐21. [MEDLINE: ] - PubMed
Olsen 1983 {published data only}
    1. Olsen JH, Friis‐Moller A, Jensen SK, Korner B, Hvidt V. Cefotaxime for prevention of infectious complications in bacteriuric men undergoing transurethral prostatic resection. A controlled comparison with methenamine. Scandinavian Journal of Urology & Nephrology 1983;17(3):299‐301. [MEDLINE: ] - PubMed
Parkhede 1982 {published data only}
    1. Parkhede U, Norberg B, Norberg A, Eriksson S. The effect of treatment with methenamine hippurate of urinary tract infection in long‐stay geriatric in‐patients with indwelling catheters: III. Evaluation by urine viscosimetry. Journal of Clinical & Experimental Gerontology 1982;4(1):71‐81. [EMBASE: 1982226624]
Parvio 1976 {published data only}
    1. Parvio S. Methenamine hippurate ('hiprex') in the treatment of chronic urinary tract infections: a trial in a geriatric hospital. Journal of International Medical Research 1976;4(2):111‐4. [MEDLINE: ] - PubMed
Pedersen 1977 {published data only}
    1. Pedersen FB, Korner B. Urinary tract infection after prostate surgery. A controlled, clinical‐bacteriological comparison between methenamine hippurate (haiprex) and phenylsalicylate methenamine preparations. Ugeskrift for Laeger 1977;139(23):1350‐2. [MEDLINE: ] - PubMed
Scetbon 1973 {published data only}
    1. Scetbon V, Peycelon‐de la Selle MF. Value of mandelamine in the prolonged treatment of urinary infections caused by escherichia coli. Therapeutique 1973;49(4):283‐6. [MEDLINE: ] - PubMed
Stover 1980 {published data only}
    1. Stover SL, Fleming WC. Recurrent bacteriuria in complete spinal cord injury patients on external condom drainage. Archives of Physical Medicine & Rehabilitation 1980;61(4):178‐82. [MEDLINE: ] - PubMed
Vainrub 1977 {published data only}
    1. Vainrub B, Musher DM. Lack of effect of methenamine in suppression of, or prophylaxis against, chronic urinary infection. Antimicrobial Agents & Chemotherapy 1977;12(5):625‐9. [MEDLINE: ] - PMC - PubMed
Wibell 1980 {published data only}
    1. Wibell L, Scheynius A, Norrman K. Methenamine‐hippurate and bacteriuria in the geriatric patient with a catheter. Acta Medica Scandinavica 1980;207(6):469‐73. [MEDLINE: ] - PubMed

Additional references

3M 2000
    1. 3M Pharmaceuticals Pty Ltd. MIMS Full prescribing information for hiprex. In: Caswell A editor(s). Mims online version 1.1. Vol. refer: MIMS OTC 1999 p. 249, MIMS Australia, Jan ‐ Mar 2000.
Albert 2004
    1. Albert X, Huertas I, Pereiro I, Sanfelix J, Gosalbes V, Perrota C. Antibiotics for preventing recurrent urinary tract infection in non‐pregnant women. Cochrane Database of Systematic Reviews 2004, Issue 3. [DOI: 10.1002/14651858.CD001209.pub2] - DOI - PMC - PubMed
Armitage 1994
    1. Armitage G, Berry G. Statistical inference. Statistical methods in medical research. 3rd Edition. Oxford: Blackwell Scientific Publications, 1994:93‐5.
Devenport 1984
    1. Devenport JK, Swenson JR, Dukes GE Jr, Sonsalla PK. Formaldehyde generation from methenamine salts in spinal cord injury. Archives of Physical Medicine & Rehabilitation 1984;65(5):257‐9. [MEDLINE: ] - PubMed
Dickersin 1994
    1. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309(6964):1286‐91. [MEDLINE: ] - PMC - PubMed
Greenwood 1981
    1. Greenwood D, Slack RC. The antibacterial activity of hexamine (methenamine), hexamine hippurate and hexamine mandelate. Infection 1981;9(5):223‐7. [MEDLINE: ] - PubMed
Hetey 1990
    1. Hetey SK. Effect of ascorbic acid on urine pH in patients with injured spinal cords. American Journal of Hospital Pharmacy 1990;37(2):235‐7. [MEDLINE: ] - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. [MEDLINE: ] - PMC - PubMed
Jepson 2004
    1. Jepson RG, Mihaljevic L, Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: 10.1002/14651858.CD001321.pub3] - DOI - PubMed
Kasanen 1974
    1. Kasanen A, Mustakallio E, Koskinen EH, Soini V. Methenamine hippurate in the treatment of urinary tract infections. Annals of Clinical Research 1974;6(5):279‐84. [MEDLINE: ] - PubMed
Lau 1998
    1. Lau J, Ioannidis JPA, Schmid CH. Summing up evidence: One answer is not always enough. Lancet 1998;351(9096):123‐7. [MEDLINE: ] - PubMed
Lefebvre 1996
    1. Lefebvre C, McDonald S. Development of a sensitive search strategy for reports of randomized controlled trials in EMBASE. Fourth International Cochrane Colloquium, Adelaide Australia, 20‐24 October. 1996.
Macfarlane 1985
    1. Macfarlane DE. Prevention and treatment of catheter‐associated urinary tract infections. Journal of Infection 1985;10(2):96‐106. [MEDLINE: ] - PubMed
Mayrer 1982
    1. Mayrer AR, Andriole VT. Urinary tract antiseptics. Medical Clinics of North America 1982;66(1):199‐208. [MEDLINE: ] - PubMed
McEvoy 1999
    1. Gerald K. McEvoy (Ed). AHFS Drug Information 1999. Bethesda: American Society of Hospital Pharmacists, 1999.
Nahata 1982
    1. Nahata MC, Cummins BA, McLeod DC, Schondelmeyer SW, Butler R. Effect of urinary acidifiers on formaldehyde concentration and efficacy with methenamine therapy. European Journal of Clinical Pharmacology 1982;22(3):281‐4. [MEDLINE: ] - PubMed
NHMRC 1999
    1. Anonymous. Summarising and synthesising the studies. How to review the evidence: systematic identification and review of the scientific literature. Canberra: NHMRC, Nov 1999:27‐36.
NIDRRS 1992
    1. National Institute on Disability and Rehabilitation Research Statement (NIDRRS). The prevention and management of urinary tract infections amongst people with spinal cord injuries. Journal of American Paraplegia Society 1992;15(3):194‐204. [MEDLINE: ] - PubMed
Niel‐Weise 2005
    1. Niel‐Weise BS, Brock PJ. Antibiotic policies for short‐term catheter bladder drainage in adults. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD005428] - DOI - PubMed
Parfitt 1999
    1. Kathleen Parfitt (ed). Martindale. London: Pharmaceutical Press, 1999.
Saint 1999
    1. Saint S, Lipsky BA. Preventing catheter‐related bacteriuria: should we? Can we? How?. Archives of Internal Medicine 1999;159(8):800‐8. [MEDLINE: ] - PubMed
Schulz 1995
    1. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408‐12. [MEDLINE: ] - PubMed
Stamm 1988
    1. Stamm WE. Protocol for diagnosis of urinary tract infection: Reconsidering the criterion for significant bacteriuria. Urology 1988;32(2 Suppl):6‐10. [MEDLINE: ] - PubMed
Thom 1999
    1. Thom JD, Wolfe V, Perkash I, Lin VW. Methicillin‐resistant Staphylococcus aureus in patients with spinal cord injury. Journal of Spinal Cord Medicine 1999;22(2):125‐31. [MEDLINE: ] - PubMed
Waites 1993
    1. Waites KB, Canupp KC, Devivo MJ. Epidemiology and risk factors for urinary tract infection following spinal cord injury. Archives of Physical Medicine & Rehabilitation 1993;74(7):691‐5. [MEDLINE: ] - PubMed
Waites 2000
    1. Waites KB, Chen Y, DeVivo MJ, Canupp KC, Moser SA. Antimicrobial resistance in gram‐negative bacteria isolated from the urinary tract in community‐residing persons with spinal cord injury. Archives of Physical Medicine & Rehabilitation 2000;81(6):764‐9. [MEDLINE: ] - PubMed
Wall 1990
    1. Wall I, Tiselius HG. Long‐term acidification of urine in patients treated for infected renal stones. Urologia Internationalis 1990;45(6):336‐41. [MEDLINE: ] - PubMed

References to other published versions of this review

Lee 2001
    1. Lee B, Bhuta T, Craig J, Simpson J. Methenamine hippurate for preventing urinary tract infections. Cochrane Database of Systematic Reviews 2001, Issue 4. [DOI: 10.1002/14651858.CD003265] - DOI - PubMed
Lee 2002
    1. Lee B, Bhuta T, Craig J, Simpson J. Methenamine hippurate for preventing urinary tract infections. Cochrane Database of Systematic Reviews 2002, Issue 1. [DOI: 10.1002/14651858.CD003265] - DOI - PubMed
Lee 2007
    1. Lee BSB, Simpson JM, Craig JC, Bhuta T. Methenamine hippurate for preventing urinary tract infections. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD003265.pub2] - DOI - PubMed

Publication types

MeSH terms